Absci (ABSI) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OmniAb (OABI) has outperformed Absci (ABSI) over the past year, gaining 166.3% versus a gain of 146.5%. Over five years, ABSI leads with a -13.3% price change compared with -53.3% for OABI. Absci is the larger company by market cap ($1.53 billion vs $677.5 million), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | OABI |
|---|---|---|
| Share price | $8.94 | $4.66 |
| Market cap | $1.53B | $677.52M |
| 1-day change | -3.04% | +2.19% |
| YTD return | +164.18% | +151.89% |
| 1-year return | +146.52% | +166.29% |
| 5-year return | -13.26% | -53.26% |
| EPS (TTM) | $-0.79 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $5.43 |
| 52-week low | $2.24 | $1.30 |
| Distance from 52-week high | -25.84% | -14.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +61.07% | +78.76% |
| Average volume | 3.45M | 1.45M |
| Shares outstanding | 171.61M | 145.39M |
| Employees | 140 | 89 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Absci is about 2.3 times larger than OmniAb by market value ($1.53B vs $677.52M).
- OABI has outperformed ABSI by 19.8 percentage points over the past year.
- The two companies sit in different sectors: Absci in Health Care and OmniAb in Healthcare.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Healthcare · Biotechnology · 89 employees
ABSI vs OABI FAQ
Which is bigger, Absci or OmniAb?
Absci (ABSI) is larger, with a market capitalization of $1.53B compared with $677.52M for OmniAb (OABI).
Which stock has performed better over the past year, ABSI or OABI?
OABI returned +166.29% over the past 12 months, compared with +146.52% for ABSI (price return, excluding dividends). Past performance does not predict future results.
Are Absci and OmniAb in the same industry?
No. Absci is in the Health Care sector, while OmniAb is in Healthcare.